BRCA2 Mutation (Q28444961)

From Wikidata

Jump to navigation Jump to search

genetic variant

MUTATION

Language	Label	Description	Also known as
English	BRCA2 Mutation	genetic variant	MUTATION

Statements

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/186

Loss Of Function Variant

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/186

human chromosome 13

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/186

32889611

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/186

32973347

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/186

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/186

positive therapeutic predictor for

determination method or standard

CIViC evidence level A

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1371

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

cediranib / olaparib combination therapy

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1678

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

triple-negative breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1685

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1773

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

statement disputed by

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

medical condition treated

triple-negative breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1776

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

pancreatic cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5913

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

determination method or standard

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2868

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6343

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

triple-negative breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1685

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

positive prognostic predictor for

surface epithelial-stromal tumor

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/465

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1676

BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/186

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28444961&oldid=2014801243"